doi: 10.1038/sj.bjp.0706406.
Cannabinoid pharmacology: the first 66 years
Affiliations
- PMID:16402100
- PMCID: PMC1760722
- DOI: 10.1038/sj.bjp.0706406
Item in Clipboard
Cannabinoid pharmacology: the first 66 years
Roger G Pertwee. Br J Pharmacol.2006 Jan.
Display options
Format
Display options
Format
Abstract
Research into the pharmacology of individual cannabinoids that began in the 1940s, several decades after the presence of a cannabinoid was first detected in cannabis, is concisely reviewed. Also described is how this pharmacological research led to the discovery of cannabinoid CB(1) and CB(2) receptors and of endogenous ligands for these receptors, to the development of CB(1)- and CB(2)-selective agonists and antagonists and to the realization that the endogenous cannabinoid system has significant roles in both health and disease, and that drugs which mimic, augment or block the actions of endogenously released cannabinoids must have important therapeutic applications. Some goals for future research are identified.
Figures
The structures of five plant cannabinoids (phytocannabinoids), Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-THC, cannabidiol (CBD), cannabinol (CBN) and Δ9-tetrahydrocannabivarin (Δ9-THCV), and of two synthetic cannabinoids, Δ6a,10a-THC and synhexyl.
The structures of two endocannabinoids, anandamide and 2-arachidonoyl glycerol.
Potential clinical strategies for the management of disorders in which an increased production of anandamide may lead to a reduction in the intensity of unwanted signs and symptoms (reviewed in Pertwee 2005c). These strategies rely on augmentation of apparent anandamide-mediated protective effects through inhibition of the cellular uptake of anandamide, through inhibition of its intracellular metabolism by fatty acid amide hydrolase or through allosteric enhancement of anandamide-induced CB1 receptor activation.
Similar articles
- Cannabinoids.Grotenhermen F.Grotenhermen F.Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):507-30. doi: 10.2174/156800705774322111.Curr Drug Targets CNS Neurol Disord. 2005.PMID:16266285Review.
- Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.Pertwee RG.Pertwee RG.Expert Opin Investig Drugs. 2000 Jul;9(7):1553-71. doi: 10.1517/13543784.9.7.1553.Expert Opin Investig Drugs. 2000.PMID:11060760Review.
- Cannabis and cannabinoids: pharmacology and rationale for clinical use.Pertwee RG.Pertwee RG.Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. doi: 10.1159/000057150.Forsch Komplementarmed. 1999.PMID:10575283Review.
- Cannabinoids and the gut: new developments and emerging concepts.Izzo AA, Sharkey KA.Izzo AA, et al.Pharmacol Ther. 2010 Apr;126(1):21-38. doi: 10.1016/j.pharmthera.2009.12.005. Epub 2010 Feb 1.Pharmacol Ther. 2010.PMID:20117132Review.
- Role of the endocannabinoid system in the development of tolerance to alcohol.Basavarajappa BS, Hungund BL.Basavarajappa BS, et al.Alcohol Alcohol. 2005 Jan-Feb;40(1):15-24. doi: 10.1093/alcalc/agh111. Epub 2004 Nov 18.Alcohol Alcohol. 2005.PMID:15550443Review.
Cited by
- Marijuana: A systems-based primer of adverse effects associated with use and an overview of its therapeutic utility.Kichloo A, Albosta M, Aljadah M, El-Amir Z, Goldar G, Khan MZ, Dahiya DS, Vallabhaneni S, Wani F, Singh J.Kichloo A, et al.SAGE Open Med. 2021 Mar 9;9:20503121211000909. doi: 10.1177/20503121211000909. eCollection 2021.SAGE Open Med. 2021.PMID:33786179Free PMC article.Review.
- Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.Ożarowski M, Karpiński TM, Zielińska A, Souto EB, Wielgus K.Ożarowski M, et al.Int J Mol Sci. 2021 Apr 21;22(9):4294. doi: 10.3390/ijms22094294.Int J Mol Sci. 2021.PMID:33919010Free PMC article.Review.
- Cancer pain management: what's new?Gaertner J, Schiessl C.Gaertner J, et al.Curr Pain Headache Rep. 2013 Apr;17(4):328. doi: 10.1007/s11916-013-0328-9.Curr Pain Headache Rep. 2013.PMID:23456796Review.
- The endocannabinoid system and pain.Guindon J, Hohmann AG.Guindon J, et al.CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21. doi: 10.2174/187152709789824660.CNS Neurol Disord Drug Targets. 2009.PMID:19839937Free PMC article.Review.
- Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond.Hempel B, Xi ZX.Hempel B, et al.Adv Pharmacol. 2022;93:275-333. doi: 10.1016/bs.apha.2021.10.006. Epub 2021 Dec 13.Adv Pharmacol. 2022.PMID:35341569Free PMC article.
References
- AGURELL S., HALLDIN M., LINDGREN J.-E., OHLSSON A., WIDMAN M., GILLESPIE H., HOLLISTER L. Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 1986;38:21–43. - PubMed
- BROWN A., WISE A.2003Identification of modulators of gpr55 activityUS Patent Document Number 20030113814 athttp://appft1.uspto.gov/netahtml/PTO/search-bool.html .
- DEVANE W.A., HANUS L., BREUER A., PERTWEE R.G., STEVENSON L.A., GRIFFIN G., GIBSON D., MANDELBAUM A., ETINGER A., MECHOULAM R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949. - PubMed
- DI MARZO V., DE PETROCELLIS L., BISOGNO T.2005The biosynthesis, fate and pharmacological properties of endocannabinoids Cannabinoids. Handbook of Experimental Pharmacologyed. Pertwee, R.G. vol. 168, pp. 147–185.Heidelburg: Springer-Verlag - PubMed
- ELSOHLY M.A.2002Chemical constituents of cannabis Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potentialeds. Grotenhermen, F. & Russo, E. pp. 27–36.New York: Haworth Press Inc
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources